Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 185Neoplasms 11Prostate Adenocarcinoma 3Neoplasm Metastasis 3Adenocarcinoma 2Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Recurrence 1Prostatic Diseases 1Primary Dysautonomias 1PSA Level Greater Than Two 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Lymphatic Metastasis 1Lower Urinary Tract Symptoms 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1

Interventions

cediranib 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Prostate Adenocarcinoma × Leuprolide × Genitourinary × Clear all
NCT04914195 2023-08-01

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Bharat Serums and Vaccines Limited

Phase 3 Completed
155 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡